{"paper_id": "1fd6ef06d7d9c8944eb8d90cb3fbb53a2e199274", "metadata": {"title": "", "authors": [{"first": "Olafia", "middle": ["S"], "last": "Gretarsdottir", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Iceland", "location": {"settlement": "Reykjavik, Reykjavik", "country": "Iceland., Iceland"}}, "email": ""}, {"first": "Thora", "middle": ["R"], "last": "Gunnarsdottir", "suffix": "", "affiliation": {"laboratory": "", "institution": "Agnar Helgason deCODE genetics/Amgen, Inc", "location": {"settlement": "Reykjavik", "country": "Iceland"}}, "email": ""}, {"first": "Hilma", "middle": [], "last": "Holm", "suffix": "", "affiliation": {"laboratory": "Landspitali -The National University Hospital, Reykjavik, Iceland. Kjartan R Gu\u00f0mundsson deCODE genetics/Amgen, Inc", "institution": "University of Iceland", "location": {"settlement": "Reykjavik, Reykjavik", "country": "Iceland., Iceland"}}, "email": ""}, {"first": "Gudrun", "middle": ["Sigmundsdottir"], "last": "Directorate", "suffix": "", "affiliation": {"laboratory": "Landspitali -The National University Hospital, Reykjavik, Iceland. Arnaldur Gylfason deCODE genetics/Amgen, Inc", "institution": "of Health", "location": {"settlement": "Reykjavik, Reykjavik, Reykjavik, Reykjavik", "country": "Iceland., Iceland, Iceland., Iceland"}}, "email": ""}, {"first": "Kristin", "middle": ["E"], "last": "Sveinsdottir", "suffix": "", "affiliation": {"laboratory": "Landspitali -The National University Hospital, Reykjavik, Iceland. Emil A Thorarensen deCODE genetics/Amgen, Inc., Reykjavik, Iceland. Bjarni Thorbjornsson deCODE genetics/Amgen, Inc", "institution": "The National University Hospital", "location": {"settlement": "Reykjavik, Reykjavik", "country": "Iceland., Iceland"}}, "email": ""}, {"first": "Maney", "middle": [], "last": "Sveinsdottir", "suffix": "", "affiliation": {"laboratory": "Gisli Masson deCODE genetics/Amgen, Inc., Reykjavik, Iceland. Investigator Affiliation Ingileif Jonsdottir deCODE genetics/Amgen, Inc., Reykjavik, Iceland. Faculty of Medicine", "institution": "University of Iceland", "location": {"settlement": "Reykjavik", "country": "Iceland"}}, "email": ""}, {"first": "Arthur", "middle": [], "last": "L\u00f6ve", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Iceland", "location": {"settlement": "Reykjavik", "country": "Iceland., Iceland., Iceland"}}, "email": ""}, {"first": "Alma", "middle": ["D"], "last": "M\u00f6ller", "suffix": "", "affiliation": {"laboratory": "", "institution": "The National University Hospital", "location": {"settlement": "Reykjavik", "country": "Iceland"}}, "email": ""}, {"first": "Thorolfur", "middle": [], "last": "Gudnason", "suffix": "", "affiliation": {"laboratory": "BioMedical Centre of the University of Iceland, Reykjavik, Iceland. Unnur Thorsteinsdottir deCODE genetics/Amgen, Inc., Reykjavik, Iceland. Faculty of Medicine", "institution": "University of Iceland", "location": {"settlement": "Reykjavik", "country": "Iceland"}}, "email": ""}, {"first": "Karl", "middle": ["G"], "last": "Kristinsson", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Iceland", "location": {"settlement": "Reykjavik, Reykjavik", "country": "Iceland., Iceland"}}, "email": ""}, {"first": "Kari", "middle": [], "last": "Stefansson", "suffix": "", "affiliation": {"laboratory": "", "institution": "University of Iceland", "location": {"settlement": "Reykjavik", "country": "Iceland"}}, "email": ""}]}, "abstract": [], "body_text": [{"text": "SARS-CoV-2 infected individuals were identified in Iceland through targeted testing and population screening. A flowchart outlining the study is shown in Figure 1 .", "cite_spans": [], "ref_spans": [{"start": 154, "end": 162, "text": "Figure 1", "ref_id": null}], "section": "SARS-COV-2 TESTING"}, {"text": "The targeted testing began on January 31 2020 and focused on individuals deemed at highrisk of being infected by SARS-CoV-2. These were mainly symptomatic (cough, fever, aches, and shortness of breath) individuals returning to Iceland from countries/regions classified by the health authorities as high-risk, or who had been in contact with infected individuals.", "cite_spans": [], "ref_spans": [], "section": "SARS-COV-2 TESTING"}, {"text": "Individuals that met the criteria for targeted testing were encouraged by the health authorities to contact the health care system for testing. They could call a specific phone number, connect through a specific website or contact their primary health care provider. A contagion tracker team tracked down contacts of infected individuals and arranged testing if they had symptoms. Sample for testing were taken in most local primary health care clinics and hospitals. In addition, a number of individuals with symptoms were tested at the international airport on arrival from high-risk areas.", "cite_spans": [], "ref_spans": [], "section": "SARS-COV-2 TESTING"}, {"text": "As of March 19, all travel outside Iceland was designated high-risk. As of March 31, 9, 199 individuals had been targeted for testing.", "cite_spans": [{"start": 75, "end": 84, "text": "March 31,", "ref_id": null}, {"start": 85, "end": 87, "text": "9,", "ref_id": null}, {"start": 88, "end": 91, "text": "199", "ref_id": null}], "ref_spans": [], "section": "SARS-COV-2 TESTING"}, {"text": "The population screening for SARS-CoV-2 was initiated by deCODE on March 13. The screening was open to all Icelandic residents who were symptom free or with mild symptoms of common cold that is highly prevalent in Iceland at this time of the year. The registration for the test was online and during sample collection information on recent travels, contacts with infected individuals, and symptoms compatible with COVID-19 were registered. The sample collection was performed in Reykjavik, the capital of Iceland. On April 1, after twenty days of population screening, 10,797 Icelanders had been screened for SARS-CoV-2.", "cite_spans": [], "ref_spans": [], "section": "SARS-COV-2 TESTING"}, {"text": "To evaluate the sampling method of the population screening, we also invited 6,782 randomly chosen Icelanders between ages 20 and 70 to participate through a phone text message sent on March 31 and April 1. Of these, 2,283 had participated by April 4 (33.7%). Of the invited, 41.2% were males and of the participants 37.8% were males.", "cite_spans": [], "ref_spans": [], "section": "SARS-COV-2 TESTING"}, {"text": "Those who tested positive for SARS-CoV-2 through any means were required to self-isolate, and those who had been in contact with them, to self-quarantine, for 2 weeks. In addition to ", "cite_spans": [], "ref_spans": [], "section": "SARS-COV-2 TESTING"}, {"text": "All individuals who tested positive for SARS-CoV-2 were contacted by phone by a contagion tracking team designated by the authorities. They were instructed to enter isolation at home.", "cite_spans": [], "ref_spans": [], "section": "TRACKING OF SARS-COV-2 INFECTIONS"}, {"text": "They were asked about their symptoms and onset, recent travels and previous contacts with infected individuals. They were also asked to identify everyone whom they had been in contact with 24 hours before noticing their first symptom and for how long they interacted with each individual and how intimate the interaction was. All registered contacts were contacted by phone, requested to go into 2 weeks quarantine and asked about symptoms.", "cite_spans": [], "ref_spans": [], "section": "TRACKING OF SARS-COV-2 INFECTIONS"}, {"text": "Those with symptoms and those who developed them in quarantine were tested for SARS-CoV-2.", "cite_spans": [], "ref_spans": [], "section": "TRACKING OF SARS-COV-2 INFECTIONS"}, {"text": "Isolation places more severe restrictions on the individual than quarantine. The Icelandic surgeon general provides detailed instructions about quarantine and isolation on the webpages https://www.covid.is/categories/how-does-quarantine-work and https://www.covid.is/categories/how-does-isolation-work. Quarantine last for fourteen days.", "cite_spans": [], "ref_spans": [], "section": "TRACKING OF SARS-COV-2 INFECTIONS"}, {"text": "Isolation ends 10 days after fever subsides or when the individual tests negative for presence of the virus. respectively. Each step in the workflow was monitored using an in-house LIMS (VirLab) with 2D barcoding (Greiner, 300 \u00b5L tubes) of all extracted samples.", "cite_spans": [], "ref_spans": [], "section": "TRACKING OF SARS-COV-2 INFECTIONS"}, {"text": "Testing for SARS-CoV-2 was performed either at LUH or deCODE using similar quantitative real-time PCR (qRT-PCR) methods. The assay at LUH is based on the WHO recommended screening method (https://www.who.int/docs/default-source/coronaviruse/wuhan-virusassay-v1991527e5122341d99287a1b17c111902.pdf), which involves a single probe panscreening assay for betacoronaviruses, followed by confirmatory measurements for all positive samples using an nCoV-2019 specific assay. The broad betacoronavirus assay is based on probes for a conserved region of the E-gene, whereas confirmatory testing assays were done using either nCoV-2019 specific probes for the RdRp gene or the TaqMan\u2122 the Ct values from the qRT-PCR assays. Figure S2 shows the relationship between measured Ct values and the consensus coverage of the sequenced samples. These data show that the qRT-PCR assay is more sensitive in detecting viral RNA than the amplicon sequencing method.", "cite_spans": [], "ref_spans": [{"start": 668, "end": 675, "text": "TaqMan\u2122", "ref_id": null}, {"start": 715, "end": 724, "text": "Figure S2", "ref_id": null}], "section": "TESTING OF SAMPLES FOR SARS-COV-2"}, {"text": "Reverse transcription (RT) and multiplex PCR was performed based on information provided by the Artic Network initiative (https://artic.network/) to generate cDNA. In short, extracted viral RNA was pre-incubated at 65 \u00b0C for 5 min in the presence of random hexamers (2.5 \u00b5M) and dNTP\u00b4s (500 \u00b5M). Sample cooling on ice was then followed by RT using SuperScript IV (ThermoFisher) in the presence of DTT (5 mM) and RNaseOUT inhibitor (ThermoFisher) for 10 min at 42\u00b0C, followed by 10 min at 70 \u00b0C. Multiplex PCR of the resulting SARS-CoV-2 cDNA was performed using a tiling scheme of primers, designed to generate overlapping amplicons of approximately 800 bp (Table S1 ). The primers were generously provided by Dr. David Stoddard at Oxford Nanopore Technologies. Two PCR reactions were done for each sample using primer pools A and B, respectively ( for at least 90% of bases were collected for each run.", "cite_spans": [], "ref_spans": [{"start": 657, "end": 666, "text": "(Table S1", "ref_id": "TABREF1"}], "section": "SAMPLE PREPARATION FOR SEQUENCING"}, {"text": "Amplicon sequences were aligned to the reference genome of the SARS-CoV-2 (NC_045512.2) 1 using bwa mem 2 , possible PCR duplicates were marked with markduplicates from Picard tools 3 and reads with less than 50 bases aligned were omitted from the alignment.", "cite_spans": [], "ref_spans": [], "section": "SEQUENCING DATA ANALYSIS"}, {"text": "The resulting aligned filtered reads were used for variant calling with bcftools 2 . For consensus sequence generation only variants reported as homozygous were used. In regions targeted with primers we allowed variants to have allele frequency below one in individual. The consensus sequence was masked with ambiguous nucleotides (N) at positions if the depth of coverage was strictly less than 5 reads after restricting to bases of quality 20 or higher.", "cite_spans": [], "ref_spans": [], "section": "SEQUENCING DATA ANALYSIS"}, {"text": "Consensus sequences with more than 10,000 ambiguous nucleotides were discarded from analysis. The SARS-COV-2 consensus sequences with less than 10,000 ambiguous nucleotides were uploaded to GISAID (https://www.gisaid.org), with virus names hCov/Iceland/1/2020-hCov/Iceland/604/2020, and EPI accession numbers, EPI_ISL_417481, EPI_ISL_417535-EPI_ISL_417876, and EPI_ISL_424367-EPI_ISL_424624. The mutations in Table S3 were used to define haplogroups/clades.", "cite_spans": [], "ref_spans": [{"start": 409, "end": 417, "text": "Table S3", "ref_id": "TABREF4"}], "section": "SEQUENCING DATA ANALYSIS"}, {"text": "In addition to calling consensus sequence of the samples independently, we jointly called variants across the samples using a modified version of Graphtyper. 4 In this modified version we excluded the termini of paired end reads overlapping a primer region. Further we supplied the following flags to Graphtyper:", "cite_spans": [{"start": 158, "end": 159, "text": "4", "ref_id": "BIBREF4"}], "ref_spans": [], "section": "SEQUENCING DATA ANALYSIS"}, {"text": "In this joint calling, we restricted to genotypes with coverage of 5 or more. We then define a carrier matrix, where the cell in matrix was 1 if the fraction of reads supporting the alternative allele (AB) was greater than 85% (carrier), and 0 if the AB was less than 5% (noncarrier). With this carrier matrix, we manually curated list of mutations in in Table S3 to define haplotypes. We then assigned a haplotype per sample, by aggregating the haplotype informative mutations of the sample and constructing a consensus haplotype.", "cite_spans": [], "ref_spans": [{"start": 355, "end": 363, "text": "Table S3", "ref_id": "TABREF4"}], "section": "SEQUENCING DATA ANALYSIS"}, {"text": "Variants were annotated using Variant Effect Predictor (VEP) version 99.2 5 in custom mode.", "cite_spans": [], "ref_spans": [], "section": "SEQUENCING DATA ANALYSIS"}, {"text": "As a gene map we used Uniprot mature gene track downloaded from UCSC 6 . A single VEP annotation was assigned to each sequence variant according to our previously described scheme (Sveinbjornsson et al 2015) using gorpipe scripts 7 .", "cite_spans": [], "ref_spans": [], "section": "SEQUENCING DATA ANALYSIS"}, {"text": "For network analysis of haplogroups a median-joining network 8 of SARS-CoV-2 sequences was generated using data from our sequencing effort in Iceland and from GISAID available on", "cite_spans": [], "ref_spans": [], "section": "SEQUENCING DATA ANALYSIS"}, {"text": "March 22 (Table S4) ", "cite_spans": [], "ref_spans": [{"start": 9, "end": 19, "text": "(Table S4)", "ref_id": "TABREF5"}], "section": "SEQUENCING DATA ANALYSIS"}, {"text": "The fraction of participants in the population screening reporting symptoms by study date.", "cite_spans": [], "ref_spans": [], "section": "Figure S4"}, {"text": "The fraction of individuals that tested positive before age 20 in the targeted testing stratified by age and sex. The results for males are shown in blue and females in red. Vertical bars indicate 95% confidence intervals. The solid curves indicate logistic regression fits of a model with a sex effect and an age effect. The dashed lines indicate 95% confidence intervals for the male and female logistic regression fits. The age odds ratio is 1.08 per year (95% CI: 1.05-1.12) and the male sex odds ratio is 1.45 (95% CI: 1.04-2.0).", "cite_spans": [], "ref_spans": [], "section": "Figure S5"}, {"text": "The fraction of individuals that tested positive in the targeted testing stratified by sex. The results for males are shown in blue and females in red. Vertical bars indicate 95% confidence intervals. The solid curves indicate logistic regression fits of a model with a sex effect, an age effect and an effect for those under 10 years of age. The dashed lines indicate 95% confidence intervals for the male and female logistic regression fits. As discussed in the main text, the fraction of positives is lower in those under 10 years of age compared to those older, but the age effect is not significant.", "cite_spans": [], "ref_spans": [], "section": "Figure S6"}, {"text": "The distribution of SARS-CoV-2 haplotypes depending on sampling and travel status. The counts of each of the eight haplotypes seen in Iceland is shown depending on whether the positive was found through early targeted testing, population screening, or later targeted testing and whether the positive had recently traveled outside Iceland. ", "cite_spans": [], "ref_spans": [], "section": "Figure S7"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "D5 GATTCTGC 6. D6 GGAGCGTC 7. D7 GGTGAACC 8. D8 AGCTCGCT 9", "authors": [{"first": "Agcgctag Ccaacaga Atattcac Aaccgcgg Cctgaact Ctgtatta Atcttagt Cctcggta Atccatat Cgagatat Acgccgca Cttagtgt Gatatcga Ttggtgag Gcgcctgt Ggttataa Ttcaggtc Tcacgccg Gctccgac Ttctaacg Gcttgcgc Tagagcgc Gtattatg Tccgacac Cgcagacg Cgcggttc Actctatg Ccaagtcc Agtagaga Acttacat Ataccaag Atgaggct Agtatctt Aacctgtt Gatagatc Aacaggaa Tatgagta Tataacct Gtctcgca", "middle": [], "last": "Ttggactt", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin", "authors": [{"first": "P", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "X-L", "middle": [], "last": "Yang", "suffix": ""}, {"first": "X-G", "middle": [], "last": "Wang", "suffix": ""}], "year": 2020, "venue": "Nature", "volume": "579", "issn": "7798", "pages": "270--273", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "Fast and accurate short read alignment with Burrows-Wheeler transform", "authors": [{"first": "H", "middle": [], "last": "Li", "suffix": ""}, {"first": "R", "middle": [], "last": "Durbin", "suffix": ""}], "year": 2009, "venue": "Bioinformatics", "volume": "25", "issn": "14", "pages": "1754--60", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Graphtyper enables populationscale genotyping using pangenome graphs", "authors": [{"first": "H", "middle": ["P"], "last": "Eggertsson", "suffix": ""}, {"first": "H", "middle": [], "last": "Jonsson", "suffix": ""}, {"first": "S", "middle": [], "last": "Kristmundsdottir", "suffix": ""}], "year": 2017, "venue": "Nat Genet", "volume": "49", "issn": "11", "pages": "1654--60", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor", "authors": [{"first": "W", "middle": [], "last": "Mclaren", "suffix": ""}, {"first": "B", "middle": [], "last": "Pritchard", "suffix": ""}, {"first": "D", "middle": [], "last": "Rios", "suffix": ""}, {"first": "Y", "middle": [], "last": "Chen", "suffix": ""}, {"first": "P", "middle": [], "last": "Flicek", "suffix": ""}, {"first": "F", "middle": [], "last": "Cunningham", "suffix": ""}], "year": 2010, "venue": "Bioinformatics", "volume": "26", "issn": "16", "pages": "2069--70", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "The Human Genome Browser at UCSC", "authors": [{"first": "W", "middle": ["J"], "last": "Kent", "suffix": ""}, {"first": "C", "middle": ["W"], "last": "Sugnet", "suffix": ""}, {"first": "T", "middle": ["S"], "last": "Furey", "suffix": ""}], "year": 2002, "venue": "Genome Res", "volume": "12", "issn": "6", "pages": "996--1006", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "GORpipe: a query tool for working with sequence data based on a Genomic Ordered Relational (GOR) architecture", "authors": [{"first": "H", "middle": [], "last": "Gu\u00f0bjartsson", "suffix": ""}, {"first": "G", "middle": ["F"], "last": "Georgsson", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Gu\u00f0j\u00f3nsson", "suffix": ""}], "year": 2016, "venue": "Bioinformatics", "volume": "32", "issn": "20", "pages": "3081--3089", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "OF CONTENT LIST OF INVESTIGATORS ............................................................................................................. 3 SUPPLEMENTARY METHODS ...................................................................................................... 5 SARS-COV-2 TESTING.............................................................................................................. 5 TRACKING OF SARS-COV-2 INFECTIONS ................................................................................. 6 RNA EXTRACTION ................................................................................................................... 7 TESTING OF SAMPLES FOR SARS-COV-2 ................................................................................. 7 SAMPLE PREPARATION FOR SEQUENCING .......................................................................... 10 ILLUMINA SEQUENCING ....................................................................................................... 11 SEQUENCING DATA ANALYSIS .............................................................................................. 12 SUPPLEMENTARY FIGURES ....................................................................................................... 15 Figure S1 Coverage of sequenced viral genomes shown as size of the consensus sequence as a function of measured Ct values from the qRT-PCR screening assays. ......................... 15 Figure S2 The number of individuals tested per day ........................................................... 16 Figure S3 Fraction of participants in (A) the targeted testing and (B) population screening that had recently traveled outside Iceland. ......................................................................... 17 Figure S4 The fraction of participants in the population screening reporting symptoms by study date. ............................................................................................................................ 18 Figure S5 The fraction of individuals that tested positive before age 20 in the targeted testing stratified by age and sex. ......................................................................................... 19 Figure S6 The fraction of individuals that tested positive in the targeted testing stratified by sex. ................................................................................................................................... 20 Figure S7 The distribution of SARS-CoV-2 haplotypes depending on sampling and travel status. ................................................................................................................................... 21 SUPPLEMENTARY TABLES ......................................................................................................... 22", "latex": null, "type": "figure"}, "FIGREF1": {"text": "isolating positives and quarantining those at high risk of infection, on March 16 the Icelandic authorities initiated a ban on gathering of over 100 people and stated that a social distancing of at least 2 meters should be maintained. On March 24, the gatherings were restricted to 20 people. To protect the elderly and other groups that are at greater risk of serious illness should they develop COVID-19 health authorities have promoted self-isolation and banned visits to nursing homes and hospitals. Although universities and colleges have been closed since March 16, daycares and elementary schools have been open. For SARS-CoV-2 testing, it was recommended to take both nasopharyngeal and oropharyngeal samples. RNA from all samples was isolated within 24 hours.", "latex": null, "type": "figure"}, "FIGREF2": {"text": "RNA samples were extracted either at the Department of Clinical Microbiology laboratory at Landspitali -the National University Hospital of Iceland (LUH) or at deCODE. Both extraction methods are based on an automated magnetic bead-purification procedure, which includes cell lysis and Proteinase K treatment. RNA from samples at LUH were extracted (32 samples per 60 min run) using the MagNA Pure LC 2.0 or MagNA Pure Compact instruments from Roche LifeScience, with 200/100 \u00b5L input/output volume(s), respectively. Samples at deCODE were extracted from swabs (96 samples per 70 min run) using the Chemagic Viral RNA kit on the Chemagic360 instrument from Perkin Elmer, with 300/100 \u00b5L input/output volume(s),", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Mix, 2019-nCoV Assay kits v1 from Thermo Fisher (three probes, see below for details). All labelled probes and primers for the E-and -RdRP genes were from TAG (Copenhagen, Denmark). Superscript\u2122 III One-Step RT-PCR assay mix with Platinum\u2122TaqDNA polymerase was from ThermoFisher. 2019 E gene control and SARS-CoV Frankfurt 1 positive controls were obtained from EVAg (https://www.european-virusarchive.com/bundle/diagnostics-controls-wuhan-coronavirus-2019-2019-ncov). Each assay was done in a 25 \u00b5L total sample volume with FAM\u2122 dye labelled probes in addition to VIC\u2122 dye labelled probes for human RNase P as internal control. Plates (96 well) were scanned in an AB-7500 Fast real-time PCR thermocycler for 40 cycles of amplification following the manufacturer\u00b4s instructions (ThermoFisher). Samples in the E-gene screening assay with Ct <35 were considered strong positive and went for confirmatory testing using RdRp, whereas samples with Ct values between 35-37 were considered weak positive and were confirmed using the TaqMan\u2122 Fast Virus method. Samples with Ct values from 37-40 were classified as inconclusive and were tested again to confirm their status. The sensitivity of the WHO assays are 5.2 RNA copies/reaction for the non-specific E-gene and 3.8 RNA copies/reaction for the 2019-nCoV specific confirmatory RdRp gene. Specificity of the WHO recommended assays were assessed against a number of known viruses, including alphacoronaviruses, non-asian strains of betacoronaviruses, influenza and MERS. No cross-reactivity was observed. deCODE used exclusively the three probe TaqMan\u2122 Fast Virus 1-step Master Mix, 2019-nCoV v1 assay described above. Both the assay kit and 2019-nCov control kits were obtained from Thermo Fisher. Assay mix A, B and C were prepared containing FAM\u2122 dye labelled probes for the SARS-CoV-2 specific genes ORF1ab, S-protein and N-protein, respectively. In addition, each assay mix contained VIC\u2122 dye labelled probes for human RNase P as internal control. Samples from 96-well RNA sample plate(s) were dispensed into three wells each in a 384 plate layout,in addition to three negative (no template) and three positive controls. Assay mix was added in a total reaction volume of 12.5 \u00b5L per sample. All sample aliquoting and mixing at deCODE was performed with an automated Hamilton STARlet 8-channel liquid handler and the assay plates were scanned in an ABI 7900 HT RT-PCR system following manufacturer\u00b4s instructions with a total of 40 cycles of amplification. Samples with FAM\u2122 dye Ct values <37 in at least two of three assays were classified as positive. Samples with FAM\u2122 dye Ct values between 37 and 40 were classified as inconclusive and their testing repeated. If repeated testing gave the same result with at least two probes the sample was classified as positive. If repeated testing gave positive results for only one probe the test was considered inconclusive and a new sample from the subject was requested. The frequency of inconclusive results was 0.04% (data not shown). Samples with undetected FAM\u2122 dye Ct values or values equal to 40 in all three assays were classified as negative if the human RNaseP assay was positive (VIC\u2122 dye Ct <40). The sensitivity of the assay was evaluated by serial dilution of the positive control and was estimated at 6 copies per reaction (data not shown). Validation of the RNA extraction and the qRT-PCR method(s) at deCODE was performed using 124 samples that had previously tested positive (n=104) or negative (n=20) with the qRT-PCR assay at LUH. All of the negative samples tested negative at deCODE and 102 of the 104 positive tested at LUH were also positive atdeCODE. Two samples that tested positive at LUH were negative at deCODE. Upon subsequent sequencing (see below) viral genome could not be detected in these two samples, probably because very few viral particles were present. Samples from 643 individuals that tested positive using either the deCODE or the LUH qPCR assays were also submitted for viral genome sequencing (see below). Viral RNA (cDNA) from six samples (0.9 %) yielded no sequence data mapping to the viral reference genome. The success of generating sequencing libraries with good coverage is highly dependent on the amount of viral RNA in the samples as assessed by", "latex": null, "type": "figure"}, "FIGREF4": {"text": ". Only sequences with start positions <=200 and stop positions >=29750 were included in the analysis. For the GISAID sequences, only those with <=1% missing nucleotides were used, whereas for the Icelandic sequences a more permissive threshold of <=5% was imposed. To reduce noise in the network, an imputation step was implemented for sequences with missing nucleotides at sites where other sequences varied, whereby the missing nucleotide was imputed to the consensus variant for the clade it was assigned to, based on non-missing sites.Contact tracking information was obtained from the Chief Epidemiologist, Directorate of Health, for 1317 confirmed cases. The information includes travel abroad, confirmed transmissions, contact with other confirmed cases as well as demographic information. The study was approved by the National Bioethics Committee of Iceland (Approval no. Coverage of sequenced viral genomes shown as size of the consensus sequence as a function of measured Ct values from the qRT-PCR screening assays. A total of 643 samples were sequenced, thereof 581 and 605 samples with coverage for at least 90% (27Kb) and 67% (20 Kb) of the genome, respectively. Six samples yielded no coverage. The number of individuals tested per day (A) in the targeted testing, (B) the open invitation part of the population screening, and (C) the random sample from the population screening. Fraction of participants in (A) the targeted testing and (B) population screening that had recently traveled outside Iceland.", "latex": null, "type": "figure"}, "TABREF0": {"text": "", "latex": null, "type": "table"}, "TABREF1": {"text": "Primers used for PCR amplification of viral cDNA for sequencing ........................ 22 Table S2 Illumina indexes used in sequencing ..................................................................... 25 Table S3 Sequence variants used to define SARS-CoV-2 clades .......................................... 28 Table S4 GISAID sequences 23.03.2020: List of contributing labs ....................................... 30 REFERENCES ............................................................................................................................. 31", "latex": null, "type": "table"}, "TABREF2": {"text": "\u00b0C, followed by thermal enzyme inactivation at 65 \u00b0C for 30 min. Adaptor ligation was done using the NEBNext\u00ae ligation master mix plus enhancer and the TruSeq unique dual indexed IDT adaptors (Illumina, Table S2). Ligation reactions were incubated for 15 min at 20 \u00b0C.", "latex": null, "type": "table"}, "TABREF3": {"text": "Primers used for PCR amplification of viral cDNA for sequencing Table S2 Illumina indexes used in sequencing GACGAGAG GTCCGTGC GCGTTGGA GCAGAATC GACGCTCC GGTTCACC AGCGAGCT GGTGAAGG AGGTGCGT AAGGATGA AAGACGTC CAGTGGAT AGACTTGG AAGGTACC CTTCACGG CACTACGA CATGCCAT CATTGTTG CAGTTCCG CCTGTGGC GAACATAC GGAAGCAG GGAGTACT TGACAAGC GAGTCCAA GGAACGTT TCCTGTAA TGTCGTAG TGCATTGC TGCCACCA TGACCTTA TTCACAAT ACATAGCG TCGTGACC ACCGGCCA CTAGCTTG CTTAAGCC AATTCTGC AGAATGCC ACCACTTA ATTGGAAC CTCTGCCT CTAGGCAA G12 TCGATATC", "latex": null, "type": "table"}, "TABREF4": {"text": "Sequence variants used to define SARS-CoV-2 clades", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Clade </td><td>Pos </td><td>Ref </td><td>Alt </td></tr><tr><td>B </td><td>28144 </td><td>T </td><td>C </td></tr><tr><td>B1 </td><td>18060 </td><td>C </td><td>T </td></tr><tr><td>B1a </td><td>17858 </td><td>A </td><td>G </td></tr><tr><td>B1a1 </td><td>17747 </td><td>C </td><td>T </td></tr><tr><td>B1a1a </td><td>24694 </td><td>A </td><td>T </td></tr><tr><td>B1a1a1 </td><td>9445 </td><td>T </td><td>C </td></tr><tr><td>B1a1a1a </td><td>17531 </td><td>T </td><td>C </td></tr><tr><td>B1a1a1a </td><td>18756 </td><td>G </td><td>T </td></tr><tr><td>B1a1a1b </td><td>29140 </td><td>G </td><td>T </td></tr><tr><td>B4 </td><td>28878 </td><td>G </td><td>A </td></tr><tr><td>B4 </td><td>29742 </td><td>G </td><td>A </td></tr><tr><td>B2 </td><td>29095 </td><td>C </td><td>T </td></tr><tr><td>A </td><td>20229 </td><td>C </td><td>T </td></tr><tr><td>A </td><td>13064 </td><td>C </td><td>T </td></tr><tr><td>A </td><td>18483 </td><td>T </td><td>C </td></tr><tr><td>A </td><td>8017 </td><td>A </td><td>G </td></tr><tr><td>A1a </td><td>11083 </td><td>G </td><td>T </td></tr><tr><td>A1a </td><td>26144 </td><td>G </td><td>T </td></tr><tr><td>A1a1 </td><td>14805 </td><td>C </td><td>T </td></tr><tr><td>A1a1a </td><td>17247 </td><td>T </td><td>C </td></tr><tr><td>A1a1a1 </td><td>5142 </td><td>C </td><td>T </td></tr><tr><td>A1a1a2 </td><td>1321 </td><td>A </td><td>C </td></tr><tr><td>A1a1a3 </td><td>3034 </td><td>T </td><td>C </td></tr><tr><td>A1a1a3 </td><td>16054 </td><td>C </td><td>T </td></tr><tr><td>A1a1a3 </td><td>17859 </td><td>T </td><td>C </td></tr><tr><td>A1a1a3 </td><td>29751 </td><td>G </td><td>C </td></tr><tr><td>A1a1a4 </td><td>1515 </td><td>A </td><td>G </td></tr><tr><td>A1a1a5 </td><td>7479 </td><td>A </td><td>G </td></tr><tr><td>A1a1b </td><td>2558 </td><td>C </td><td>T </td></tr><tr><td>A1a2 </td><td>7876 </td><td>T </td><td>A </td></tr><tr><td>A3 </td><td>1397 </td><td>G </td><td>A </td></tr><tr><td>A3 </td><td>11083 </td><td>G </td><td>T </td></tr><tr><td>A3 </td><td>28688 </td><td>T </td><td>C </td></tr><tr><td>A3 </td><td>29742 </td><td>G </td><td>T </td></tr><tr><td>A6 </td><td>514 </td><td>T </td><td>C </td></tr><tr><td>A7 </td><td>9924 </td><td>C </td><td>T </td></tr></table></body></html>"}, "TABREF5": {"text": "GISAID sequences 23.03.2020: List of contributing labs. See excel document.", "latex": null, "type": "table"}}, "back_matter": [{"text": " A10  27806 G  T  A10  29711 G  T  A2  241 C  T  A2  3037 C  T  A2  23403 A  G  A2a 14408The clade nomenclature at ncov-NextStrain (https://academic.oup.com/bioinformatics/article/34/23/4121/5001388) was used as a basis for our clade definitions and we added clades in accordance with the phylogenetic tree at NextStrain (at 2020-04-04).", "cite_spans": [], "ref_spans": [{"start": 1, "end": 83, "text": "A10  27806 G  T  A10  29711 G  T  A2  241 C  T  A2  3037 C  T  A2  23403 A  G  A2a", "ref_id": null}], "section": "annex"}]}